PRZOOM - /newswire/ -
Cologne, North Rhine-Westphalia, Germany, 2020/09/15 - Due to the continuous strong demand for disinfectants, specialty chemicals company LANXESS is planning to expand its production capacity for Oxone monopersulfate by around 50 percent - LANXESS.com. FRA: DE Frankfurt: LXS
• Production increase of around 50 percent targeted;
• Investment amount in the lower double-digit million euro range;
• Significant increase in demand due to African swine fever and corona pandemic;
• Long-term trend towards more disinfection and increasing demand for powerful oxidizing agents.
To this end, the company intends to invest a lower double-digit million euro sum in its production facility in Memphis, USA.
LANXESS uses Oxone monopersulfate as the main active ingredient in many of its Virkon and Rely+On disinfection products. Demand for these products has increased significantly in recent months due to, amongst others, the outbreak of African swine fever as well as the corona pandemic. The company also sells Oxone as a powerful oxidizing agent for numerous other applications. The capacity expansion is expected to be completed in the second half of 2022.
“Disinfection products are important growth drivers in our highly profitable Consumer Protection segment. We expect a sustainable high level of demand even after the corona pandemic,” said Matthias Zachert, Chairman of the LANXESS Board of Management.
Michael Schäfer, head of LANXESS' Material Protection Products business unit, added: “We are also seeing a growing demand for Oxone in the water treatment sector as well as from the electronics and paper industries. We want to meet this demand by expanding our production capacity.”
Long-term trend towards more disinfection and increasing demand for oxidizing agents
Under the umbrella brand Virkon, LANXESS develops and sells products that agricultural businesses use for disinfection purposes. These products help to contain the spread of diseases such as African swine fever or avian influenza and make a sustainable contribution to reducing the use of antibiotics in the animal husbandry industry. The topic of biosecurity also continues to gain importance due to the increasing populations and meat consumption, which in turn leads to a sustained growth in demand for disinfectants.
LANXESS also offers disinfectants for human health: The product Rely+On Virkon is used in hospitals, laboratories, public institutions and for medical equipment. It is proven to completely inactivate the coronavirus SARS-CoV-2 in only 60 seconds.
Oxone is used, for example, to clean pool water, thereby reducing the use of chlorine. In the electronics industry, it is applied to prepare surfaces within the production process of printed circuit boards. Paper manufacturers use the product to effectively break down paper products containing wet strength resins during paper reprocessing. In addition, Oxone is a primary component of denture cleansers. Demand in these industries is growing, not least because regulatory requirements are becoming stricter and customers increasingly prefer chlorine-free oxidation solutions.
LANXESS (lanxess.com) is a leading specialty chemicals company with sales of EUR 7.2 billion in 2018. The company currently has about 15,500 employees in 33 countries and is represented at 57 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.